𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug

✍ Scribed by Nabil F. Saba; Xu Wang; Susan Müller; Mourad Tighiouart; Kwangjae Cho; Shuming Nie; Zhuo (Georgia) Chen; Dong M. Shin

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
359 KB
Volume
31
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Nanotechnology‐based drug delivery approaches may help increase therapeutic efficacy and decrease side effects of chemotherapeutics. We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as a target for nanotherapy.

Methods

Folate receptor expression levels in archival SCCHN tissues were analyzed by immunohistochemistry and correlated with clinical parameters.

Results

Folate receptor was detected in 45% of primary tumors and 40% of corresponding lymph node metastases. Folate receptor expression in primary tumors of the metastatic group strongly correlated with the corresponding lymph node metastases (p = .0002). Folate receptor expression was inversely correlated with disease‐free survival in nonmetastatic (p = .0048), metastatic (p = .0127), and lymph node metastases (p <.001) groups, and with overall survival in the lymph node metastases group (p <.0001).

Conclusion

Folate receptor is expressed in a significant proportion of primary SCCHN and corresponding lymph node metastases tissues, and correlates with worse clinical outcome. These findings provide support for folate receptor‐mediated nanotherapeutics in SCCHN. © 2008 Wiley Periodicals, Inc. Head Neck, 2009

📜 SIMILAR VOLUMES

Altered metabolism in head and neck squa
Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets
✍ Vlad C. Sandulache; Jeffrey N. Myers 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

## Abstract Tumor cells were first shown to exhibit a distinct metabolic phenotype over 80 years ago. Since then, it has become clear that multiple oncogenic events contribute to the development of a metabolic phenotype that supports rapid proliferation. Because this phenotype represents an essenti

Identification of a novel therapeutic ta
Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway
✍ Satoya Shimizu; Jun Tsukada; Takashi Sugimoto; Naoko Kikkawa; Keita Sasaki; Hide 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 321 KB 👁 1 views

## Abstract Distant metastasis is a major factor associated with poor prognosis in head and neck squamous cell carcinomas (HNSCC), but little is known of its molecular mechanisms. New markers that predict clinical outcome, in particular the ability of primary tumors to develop metastatic tumors, ar

Role of squamous cell carcinoma antigen
Role of squamous cell carcinoma antigen 1 expression in the invasive potential of head and neck squamous cell carcinoma
✍ Torahiko Nakashima; Ryuji Yasumatsu; Yuichiro Kuratomi; Muneyuki Masuda; Takashi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 2 views

## Background: Serine proteases have important roles in tumor invasion and metastasis, and their inhibitors, serine protease inhibitors (serpins), are attractive targets for therapeutic strategies. on chromosome 18q21, there is a cluster of serpins: maspin, headpin, and squamous cell carcinoma anti

A suggested method for sentinel node bio
A suggested method for sentinel node biopsy in squamous cell carcinoma of the head and neck
✍ Taimur Shoaib; David S. Soutar; Joanne E. Prosser; David J. Dunaway; Henry W. Gr 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Background. Debate continues over the management of the N0 neck in head and neck malignancy. Therefore, the possibility of performing sentinel node biopsy in these patients was investigated to formulate a method for the procedure. Methods. Patients undergoing prophylactic or therapeutic neck dissec

Targeted molecular therapy of head and n
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model
✍ Daisuke Sano; David R. Fooshee; Mei Zhao; Genevieve A. Andrews; Mitchell J. Fred 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 2 views

## Abstract ## Background We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR‐2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carci